Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other financing activities: 2016-2024

Historic Other financing activities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Dec 2024 value amounting to -$12.9 million.

  • Iovance Biotherapeutics' Other financing activities rose 92.61% to -$464,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 38.41%. This contributed to the annual value of -$12.9 million for FY2024, which is 360.04% down from last year.
  • Iovance Biotherapeutics' Other financing activities amounted to -$12.9 million in FY2024, which was down 360.04% from -$2.8 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Other financing activities ranged from a high of -$284,000 in FY2020 and a low of -$12.9 million during FY2024.
  • Its 3-year average for Other financing activities is -$6.1 million, with a median of -$2.8 million in 2023.
  • In the last 5 years, Iovance Biotherapeutics' Other financing activities grew by 8.97% in 2020 and then crashed by 360.04% in 2024.
  • Yearly analysis of 4 years shows Iovance Biotherapeutics' Other financing activities stood at -$284,000 in 2020, then reached -$2.6 million in 2022, then decreased by 5.51% to -$2.8 million in 2023, then tumbled by 360.04% to -$12.9 million in 2024.